Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives Average Recommendation of “Hold” from Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has been assigned an average rating of “Hold” from the eleven analysts that are covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $4.79.

MRNS has been the subject of a number of research reports. StockNews.com assumed coverage on shares of Marinus Pharmaceuticals in a report on Sunday. They set a “sell” rating for the company. Oppenheimer upgraded Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 target price on the stock in a report on Monday, September 23rd. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. Cantor Fitzgerald reissued an “overweight” rating and issued a $4.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. Finally, Royal Bank of Canada decreased their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a report on Friday, October 25th.

Marinus Pharmaceuticals Trading Down 0.1 %

Shares of NASDAQ MRNS opened at $0.53 on Wednesday. The firm has a 50-day moving average of $0.33 and a two-hundred day moving average of $1.03. The company has a market capitalization of $29.43 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a twelve month low of $0.22 and a twelve month high of $11.26.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals during the 2nd quarter valued at $813,000. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the 2nd quarter worth about $727,000. XTX Topco Ltd purchased a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $232,000. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $28,000. Finally, Squarepoint Ops LLC acquired a new position in Marinus Pharmaceuticals in the second quarter worth approximately $206,000. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.